Latest Breaking News On - Oncology division - Page 7 : comparemela.com

Dr Lamanna on the Use of Novel Agents Following Progression in CLL

Nicole Lamanna, MD, discusses how the use of novel agents could address resistance associated with current treatment options for patients with chronic lymphocytic leukemia.

Nicole lamannaHematology oncology divisionColumbia universityNational comprehensive cancer network guidelinesHerbert irving comprehensive cancer centerHematologic malignancies sectionOncology divisionNational comprehensive cancer networkColumbia university herbert irving comprehensive cancer centerOnclive tvChronic lymphocytic leukemia

Overcoming Resistance Mutations Is a Focus for Novel Therapies in R/R CLL

Nicole Lamanna, MD, discusses the challenges of resistance in patients with CLL, highlights treatment being developed for patients who progress on BTK inhibitor– or venetoclax-based regimens, and emphasizes the need for further enrollment onto clinical trials.

New yorkUnited statesNicole lamannaNational comprehensive cancer network guidelinesHematologic malignancies sectionOncology divisionColumbia universityHerbert irving comprehensive cancerNational comprehensive cancer networkColumbia university herbert irving comprehensive cancer centerChronic lymphocytic leukemiaHematologic malignancies

Pioneering Sylvester physician elected to Society of Neuro-Oncology Board

Pioneering Sylvester physician elected to Society of Neuro-Oncology Board
communitynewspapers.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from communitynewspapers.com Daily Mail and Mail on Sunday newspapers.

Sunny isles beachUnited statesCoral gablesCoconut groveMiami dade countyMiami beachCutler bayMemorial sloan kettering cancer centerNew yorkSouth miamiBritish columbiaPalmetto bayUniversity of miami miller school medicineOncology divisionSociety of neuroSylvester comprehensive cancer center

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and

Received FDA Agreement Under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical TrialPositive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing Phase 2 Clinical Trial with Suprachoroidal Administration Presented at AAO 2023Preliminary Data from Phase 1 Trial in.

United statesLos pinosJ jill hopkinsMark plavsicTechnology officerSuprachoroidal administrationNovartis companyOncology divisionCompany phaseAura biosciences incExchange commissionExploratory development at novartisCompany global phaseUnder special protocol assessmentCompass phaseClinical efficacy updates

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Received FDA Agreement Under Special Protocol Assessment for the CoMpass Phase 3 Clinical Trial Positive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing.

United statesMark plavsicLos pinosJ jill hopkinsTechnology officerCompany phaseExchange commissionExploratory development at novartisNovartis companyAura biosciences incOncology divisionCompany global phaseAura biosciencesElisabet de los pinosChief executive officerCompass phase